Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Chiò A[au]:

Amyotrophic lateral sclerosis. Hardiman O et al. Nat Rev Dis Primers. (2017)

Amyotrophic lateral sclerosis. van Es MA et al. Lancet. (2017)

Pain in amyotrophic lateral sclerosis. Chiò A et al. Lancet Neurol. (2017)

Search results

Items: 1 to 50 of 337

1.

Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR.

Peters S, Visser AE, D'Ovidio F, Vlaanderen J, Portengen L, Beghi E, Chio A, Logroscino G, Hardiman O, Pupillo E, Veldink JH, Vermeulen R, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Aug 21. pii: jnnp-2019-320986. doi: 10.1136/jnnp-2019-320986. [Epub ahead of print]

PMID:
31434759
2.

Divining progression in Parkinson disease with a blood test: NfL.

Boylan LS, Chiò A.

Neurology. 2019 Sep 10;93(11):471-472. doi: 10.1212/WNL.0000000000008087. Epub 2019 Aug 16. No abstract available.

PMID:
31420460
3.

Cognitive impairment across ALS clinical stages in a population-based cohort.

Chiò A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, Barberis M, Corrado L, D'Alfonso S, Bersano E, Sarnelli MF, Solara V, Zucchetti JP, Peotta L, Iazzolino B, Mazzini L, Mora G, Calvo A.

Neurology. 2019 Sep 3;93(10):e984-e994. doi: 10.1212/WNL.0000000000008063. Epub 2019 Aug 13.

PMID:
31409738
4.

Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort.

Corrado L, Brunetti M, Di Pierro A, Barberis M, Croce R, Bersano E, De Marchi F, Zuccalà M, Barizzone N, Calvo A, Moglia C, Mazzini L, Chiò A, D'Alfonso S.

Neurol Sci. 2019 Dec;40(12):2537-2540. doi: 10.1007/s10072-019-04001-3. Epub 2019 Jul 9.

PMID:
31286297
5.

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O; AB10015 STUDY GROUP.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 7:1-10. doi: 10.1080/21678421.2019.1632346. [Epub ahead of print]

PMID:
31280619
6.

Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients.

Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurrò MR, Tedeschi G, Mandrioli J.

Front Neurosci. 2019 May 17;13:485. doi: 10.3389/fnins.2019.00485. eCollection 2019.

7.

Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).

Mandrioli J, Crippa V, Cereda C, Bonetto V, Zucchi E, Gessani A, Ceroni M, Chio A, D'Amico R, Monsurrò MR, Riva N, Sabatelli M, Silani V, Simone IL, Sorarù G, Provenzani A, D'Agostino VG, Carra S, Poletti A.

BMJ Open. 2019 May 30;9(5):e028486. doi: 10.1136/bmjopen-2018-028486.

8.
9.

Gene-Environment-Time Interactions in Neurodegenerative Diseases: Hypotheses and Research Approaches.

Bradley WG, Andrew AS, Traynor BJ, Chiò A, Butt TH, Stommel EW.

Ann Neurosci. 2018 Dec;25(4):261-267. doi: 10.1159/000495321. Epub 2018 Dec 4.

10.

A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression.

Zandonà A, Vasta R, Chiò A, Di Camillo B.

BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):118. doi: 10.1186/s12859-019-2692-x.

11.

Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis.

Dekker AM, Diekstra FP, Pulit SL, Tazelaar GHP, van der Spek RA, van Rheenen W, van Eijk KR, Calvo A, Brunetti M, Damme PV, Robberecht W, Hardiman O, McLaughlin R, Chiò A, Sendtner M, Ludolph AC, Weishaupt JH, Pardina JSM, van den Berg LH, Veldink JH.

Sci Rep. 2019 Apr 11;9(1):5931. doi: 10.1038/s41598-019-42091-3.

12.

Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study.

Calvo A, Chiò A, Pagani M, Cammarosano S, Dematteis F, Moglia C, Solero L, Manera U, Martone T, Brunetti M, Balma M, Castellano G, Barberis M, Cistaro A, Artusi CA, Vasta R, Montanaro E, Romagnolo A, Iazzolino B, Canosa A, Carrara G, Valentini C, Li TQ, Nobili F, Lopiano L, Rizzone MG.

J Neurol. 2019 Jul;266(7):1633-1642. doi: 10.1007/s00415-019-09305-0. Epub 2019 Apr 4.

PMID:
30949819
13.

Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk.

Visser AE, D'Ovidio F, Peters S, Vermeulen RC, Beghi E, Chiò A, Veldink JH, Logroscino G, Hardiman O, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):854-860. doi: 10.1136/jnnp-2018-319779. Epub 2019 Mar 8.

PMID:
30850472
14.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8.

15.

Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis.

Thurn T, Borasio GD, Chiò A, Galvin M, McDermott CJ, Mora G, Sermeus W, Winkler AS, Anneser J.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):74-81. doi: 10.1080/21678421.2018.1536154. Epub 2019 Feb 21.

PMID:
30789031
16.

Validation of the revised classification of cognitive and behavioural impairment in ALS.

Iazzolino B, Pain D, Peotta L, Calvo A, Moglia C, Canosa A, Manera U, Ilardi A, Bombaci A, Zucchetti JP, Mora G, Chio A.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):734-739. doi: 10.1136/jnnp-2018-319696. Epub 2019 Feb 7.

PMID:
30733331
17.

Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis.

Marini C, Morbelli S, Cistaro A, Campi C, Caponnetto C, Bauckneht M, Bellini A, Buschiazzo A, Calamia I, Beltrametti MC, Margotti S, Fania P, Poggi I, Cabona C, Capitanio S, Piva R, Calvo A, Moglia C, Canosa A, Massone A, Nobili F, Mancardi G, Chiò A, Piana M, Sambuceti G.

Brain. 2018 Aug 1;141(8):2272-2279. doi: 10.1093/brain/awy152.

18.

Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.

Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G; ITALSGEN Consortium; International ALS Genomics Consortium, Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chiò A, Traynor BJ.

Ann Neurol. 2019 Apr;85(4):470-481. doi: 10.1002/ana.25431. Epub 2019 Mar 13.

PMID:
30723964
19.

Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.

Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L; ALS Stratification Consortium, Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G.

Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4.

20.

Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis.

Peters S, Visser AE, D'Ovidio F, Beghi E, Chiò A, Logroscino G, Hardiman O, Kromhout H, Huss A, Veldink J, Vermeulen R, van den Berg LH; Euro-MOTOR Consortium.

Am J Epidemiol. 2019 Apr 1;188(4):796-805. doi: 10.1093/aje/kwy287.

PMID:
30649156
21.

Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort.

Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D'Ovidio F, Bombaci A, Bersano E, Mazzini L, Mora G, Chiò A; Piemonte and Valle d’Aosta Register for ALS (PARALS).

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):666-673. doi: 10.1136/jnnp-2018-319611. Epub 2019 Jan 10.

PMID:
30630957
22.

Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.

Sala A, Iaccarino L, Fania P, Vanoli EG, Fallanca F, Pagnini C, Cerami C, Calvo A, Canosa A, Pagani M, Chiò A, Cistaro A, Perani D.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1117-1131. doi: 10.1007/s00259-018-4246-2. Epub 2019 Jan 7.

PMID:
30617963
23.

Concentrated pineapple juice for visualisation of the oesophagus during magnetic resonance angiography before atrial fibrillation radiofrequency catheter ablation.

Faletti R, Gatti M, Di Chio A, Fronda M, Anselmino M, Ferraris F, Gaita F, Fonio P.

Eur Radiol Exp. 2018 Nov 21;2(1):39. doi: 10.1186/s41747-018-0067-0.

24.

Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis.

Canosa A, Pagani M, Brunetti M, Barberis M, Iazzolino B, Ilardi A, Cammarosano S, Manera U, Moglia C, Calvo A, Cistaro A, Chiò A.

Eur J Neurol. 2019 Feb;26(2):306-312. doi: 10.1111/ene.13812. Epub 2018 Oct 24.

PMID:
30240096
25.

A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms.

Canosa A, De Marco G, Lomartire A, Rinaudo MT, Di Cunto F, Turco E, Barberis M, Brunetti M, Casale F, Moglia C, Calvo A, Marklund SL, Andersen PM, Mora G, Chiò A.

Neurobiol Aging. 2018 Dec;72:189.e11-189.e17. doi: 10.1016/j.neurobiolaging.2018.08.014. Epub 2018 Aug 24.

PMID:
30236613
26.

Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study.

D'Ovidio F, Rooney JPK, Visser AE, Manera U, Beghi E, Logroscino G, Vermeulen RCH, Veldink JH, van den Berg LH, Hardiman O, Chiò A; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):11-19. doi: 10.1136/jnnp-2018-318559. Epub 2018 Aug 3.

PMID:
30076269
27.

The multistep hypothesis of ALS revisited: The role of genetic mutations.

Chiò A, Mazzini L, D'Alfonso S, Corrado L, Canosa A, Moglia C, Manera U, Bersano E, Brunetti M, Barberis M, Veldink JH, van den Berg LH, Pearce N, Sproviero W, McLaughlin R, Vajda A, Hardiman O, Rooney J, Mora G, Calvo A, Al-Chalabi A.

Neurology. 2018 Aug 14;91(7):e635-e642. doi: 10.1212/WNL.0000000000005996. Epub 2018 Jul 25.

28.

Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).

Mandrioli J, D'Amico R, Zucchi E, Gessani A, Fini N, Fasano A, Caponnetto C, Chiò A, Dalla Bella E, Lunetta C, Mazzini L, Marinou K, Sorarù G, de Biasi S, Lo Tartaro D, Pinti M, Cossarizza A; RAP-ALS investigators group.

Medicine (Baltimore). 2018 Jun;97(24):e11119. doi: 10.1097/MD.0000000000011119.

29.

Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls.

D'hulst L, Van Weehaeghe D, Chiò A, Calvo A, Moglia C, Canosa A, Cistaro A, Willekens SM, De Vocht J, Van Damme P, Pagani M, Van Laere K.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):570-577. doi: 10.1080/21678421.2018.1476548. Epub 2018 Jun 4.

PMID:
29862846
30.

Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis.

Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, Brito-Armas JM, Kalmar B, Ule A, Yu Y, Birsa N, Bodo C, Collins T, Conicella AE, Mejia Maza A, Marrero-Gagliardi A, Stewart M, Mianne J, Corrochano S, Emmett W, Codner G, Groves M, Fukumura R, Gondo Y, Lythgoe M, Pauws E, Peskett E, Stanier P, Teboul L, Hallegger M, Calvo A, Chiò A, Isaacs AM, Fawzi NL, Wang E, Housman DE, Baralle F, Greensmith L, Buratti E, Plagnol V, Fisher EM, Acevedo-Arozena A.

EMBO J. 2018 Jun 1;37(11). pii: e98684. doi: 10.15252/embj.201798684. Epub 2018 May 15.

31.

Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis.

Visser AE, Rooney JPK, D'Ovidio F, Westeneng HJ, Vermeulen RCH, Beghi E, Chiò A, Logroscino G, Hardiman O, Veldink JH, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):797-803. doi: 10.1136/jnnp-2017-317724. Epub 2018 Apr 23.

PMID:
29685899
32.

Referral bias in ALS epidemiological studies.

Logroscino G, Marin B, Piccininni M, Arcuti S, Chiò A, Hardiman O, Rooney J, Zoccolella S, Couratier P, Preux PM, Beghi E; for EURALS.

PLoS One. 2018 Apr 16;13(4):e0195821. doi: 10.1371/journal.pone.0195821. eCollection 2018.

33.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

34.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

35.

Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis.

Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, Lunetta C, Marinou K, Ticozzi N, Drago Ferrante G, Scialo C, Sorarù G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurrò MR, Sabatelli M, Chiò A, Riva N, Logroscino G, Messina S, Calvo A.

Eur J Neurol. 2018 Jun;25(6):861-868. doi: 10.1111/ene.13620. Epub 2018 Apr 15.

36.

Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a population-based cluster analysis.

Vasta R, Calvo A, Moglia C, Cammarosano S, Manera U, Canosa A, D'Ovidio F, Mazzini L, Chiò A.

Eur J Neurol. 2018 May;25(5):756-761. doi: 10.1111/ene.13586. Epub 2018 Mar 25.

PMID:
29377594
37.

NADPH oxidases 2 activation in patients with Parkinson's disease.

Marrali G, Casale F, Salamone P, Fuda G, Ilardi A, Manera U, Calvo A, Zibetti M, Lopiano L, Chiò A.

Parkinsonism Relat Disord. 2018 Apr;49:110-111. doi: 10.1016/j.parkreldis.2018.01.003. Epub 2018 Jan 5. No abstract available.

PMID:
29331562
38.

Amyotrophic lateral sclerosis and food intake.

Pupillo E, Bianchi E, Chiò A, Casale F, Zecca C, Tortelli R, Beghi E; SLALOM Group; PARALS Group; SLAP Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):267-274. doi: 10.1080/21678421.2017.1418002. Epub 2017 Dec 21.

39.

Reconsidering the causality of TIA1 mutations in ALS.

van der Spek RA, van Rheenen W, Pulit SL, Kenna KP, Ticozzi N, Kooyman M, Mclaughlin RL, Moisse M, van Eijk KR, van Vugt JJFA, Iacoangeli A, Andersen P, Nazli Basak A, Blair I, de Carvalho M, Chio A, Corcia P, Couratier P, Drory VE, Glass JD, Hardiman O, Mora JS, Morrison KE, Mitne-Neto M, Robberecht W, Shaw PJ, Panadés MP, van Damme P, Silani V, Gotkine M, Weber M, van Es MA, Landers JE, Al-Chalabi A, van den Berg LH, Veldink JH; PROJECT MINE ALS SEQUENCING CONSORTIUM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):1-3. doi: 10.1080/21678421.2017.1413118. Epub 2017 Dec 13. No abstract available. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):161.

40.

Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.

Chia R, Chiò A, Traynor BJ.

Lancet Neurol. 2018 Jan;17(1):94-102. doi: 10.1016/S1474-4422(17)30401-5. Epub 2017 Nov 16. Review.

41.

G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo.

Simone R, Balendra R, Moens TG, Preza E, Wilson KM, Heslegrave A, Woodling NS, Niccoli T, Gilbert-Jaramillo J, Abdelkarim S, Clayton EL, Clarke M, Konrad MT, Nicoll AJ, Mitchell JS, Calvo A, Chio A, Houlden H, Polke JM, Ismail MA, Stephens CE, Vo T, Farahat AA, Wilson WD, Boykin DW, Zetterberg H, Partridge L, Wray S, Parkinson G, Neidle S, Patani R, Fratta P, Isaacs AM.

EMBO Mol Med. 2018 Jan;10(1):22-31. doi: 10.15252/emmm.201707850.

42.

Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium.

Pupillo E, Poloni M, Bianchi E, Giussani G, Logroscino G, Zoccolella S, Chiò A, Calvo A, Corbo M, Lunetta C, Marin B, Mitchell D, Hardiman O, Rooney J, Stevic Z, Bandettini di Poggio M, Filosto M, Cotelli MS, Perini M, Riva N, Tremolizzo L, Vitelli E, Damiani D, Beghi E; EURALS Consortium†.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):118-125. doi: 10.1080/21678421.2017.1386687. Epub 2017 Oct 24.

PMID:
29063790
43.

Amyotrophic lateral sclerosis.

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH.

Nat Rev Dis Primers. 2017 Oct 20;3:17085. doi: 10.1038/nrdp.2017.85.

PMID:
29052611
44.

Amyotrophic lateral sclerosis.

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH.

Nat Rev Dis Primers. 2017 Oct 5;3:17071. doi: 10.1038/nrdp.2017.71. Review. Erratum in: Nat Rev Dis Primers. 2017 Oct 20;3:17085.

45.

Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.

van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, Young CA, Shaw CE, Mora G, Mandrioli J, Borghero G, Volanti P, Diekstra FP, van Rheenen W, Verstraete E, Eijkemans MJC, Veldink JH, Chio A, Al-Chalabi A, van den Berg LH, van Es MA; For UKMND-LiCALS and LITALS Study Group.

Neurology. 2017 Oct 31;89(18):1915-1922. doi: 10.1212/WNL.0000000000004606. Epub 2017 Oct 4. Review. Erratum in: Neurology. 2017 Nov 28;89(22):2303.

46.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. No abstract available.

47.

The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis.

D'Ovidio F, d'Errico A, Carnà P, Calvo A, Costa G, Chiò A.

Eur J Neurol. 2018 Jan;25(1):164-170. doi: 10.1111/ene.13465. Epub 2017 Oct 21.

PMID:
28921834
48.

Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort.

Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Drago Ferrante G, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Poletti B, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurrò MR, Tedeschi G, Mandrioli J.

J Neurol. 2017 Nov;264(11):2224-2231. doi: 10.1007/s00415-017-8619-4. Epub 2017 Sep 15.

PMID:
28914354
49.

A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR.

Rooney JPK, Visser AE, D'Ovidio F, Vermeulen R, Beghi E, Chio A, Veldink JH, Logroscino G, van den Berg LH, Hardiman O; Euro-MOTOR Consortium.

Neurology. 2017 Sep 19;89(12):1283-1290. doi: 10.1212/WNL.0000000000004390. Epub 2017 Aug 23.

PMID:
28835399
50.

NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?

Sorce S, Stocker R, Seredenina T, Holmdahl R, Aguzzi A, Chio A, Depaulis A, Heitz F, Olofsson P, Olsson T, Duveau V, Sanoudou D, Skosgater S, Vlahou A, Wasquel D, Krause KH, Jaquet V.

Free Radic Biol Med. 2017 Nov;112:387-396. doi: 10.1016/j.freeradbiomed.2017.08.006. Epub 2017 Aug 12. Review.

Supplemental Content

Support Center